Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Exposure to Articaine (AG-920) in Healthy Subjects
NCT04759339Phase 1Completed
- Sponsor
- American Genomics
- Start
- Feb 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of articaine in procedural pain, sponsored by American Genomics. Primary endpoint: Systemic exposure to articaine and its metabolite after dosing a single topical ocular administration of AG-920 at 8 hours. Started Feb 2021; status: completed.
02
Drugs
articaine
03
Conditions
procedural pain
Beyond the preview
Go deeper on NCT04759339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759339.